Roche sketches out Blueprint collaboration

Drug discovery startup Blueprint Medicines has agreed a research collaboration with Roche to develop small molecule drugs aimed at cancer immunotherapy targets.

Blueprint specialises in developing molecules that interact with kinases – enzymes that add phosphate groups onto other proteins or substrate molecules. Kinases are involved in numerous cell-signalling pathways. The projects covered by this deal relate to kinases implicated in modulating our immune system’s response to tumours. Roche is one of a host of companies developing new cancer medicines that harness the immune system.

The deal is heavily performance-related. Roche will pay $45 million (£31 million) up front, with up to $965 million on offer as projects progress, plus royalties on any products that make it to market.

Related Content

Pharma queues up for checkpoint inhibitor collaborations

3 July 2015 Business

news image

Combinations of different firms’ drugs seek to reap immuno-oncology’s benefits

Viral cancer therapy approved in the US

11 November 2015 Business

news image

T-Vec is the first approved oncolytic virus, but its limited treatment scope means it is unlikely to become a blockbuster

Most Commented

Beyond element 118: the next row of the periodic table

29 January 2016 News and Analysis

news image

A technological leap may be called for to expand the number of elements in existence

New German excellence strategy gets political go-ahead

21 June 2016 News and Analysis

news image

Scheme will provide €500 million to bolster country’s best universities and fund best research